Calling amphetamine a dopamine reuptake blocker captures only part of the pharmacology discussed in Heal and colleagues’ 2013 review. The paper describes amphetamine as a competitive transporter substrate that can enter nerve terminals and promote monoamine release. That distinction matters when comparing drugs with superficially similar effects on extracellular dopamine.
Reuptake inhibition and release are different processes
Monoamine transporters normally help move neurotransmitters from the space outside a neuron back into the nerve terminal. A classical reuptake inhibitor can reduce that movement by blocking transporter function. Amphetamine can compete as a transported substrate instead. The same observation—less uptake of a labeled neurotransmitter in an assay—does not establish an identical underlying mechanism.
The review discusses dopamine, norepinephrine and serotonin transporters separately. “Monoamine” is a family term, not another name for dopamine. An account confined to dopamine can omit actions relevant to both behavioral and peripheral physiological effects.
The intracellular step changes the explanation
The review describes two relevant neurotransmitter pools: one in the cytosol and another in storage vesicles. Vesicular monoamine transporter 2, or VMAT2, helps move monoamines into the storage compartment. Amphetamine’s effects on intracellular handling can increase the monoamines available for movement out of the nerve terminal.
In the reviewed model, transporter direction can reverse, producing outward movement into the synapse. The authors call this reverse transport. They also discuss reuptake inhibition and possible monoamine oxidase inhibition as contributing actions, rather than presenting one isolated process as the entire explanation.
These are mechanistic accounts derived substantially from experimental preparations and animal work. Their existence does not establish the magnitude or timing of each contribution in a particular human exposure.
Laboratory potency is not a blood impairment cutoff
The review tabulates uptake-inhibition constants from rat-brain synaptosome experiments. Such constants characterize an assay under specified experimental conditions. They are not measured blood concentrations in treated patients or drivers, and they should not be relabeled as therapeutic, toxic or impairment thresholds.
Different preparations and study conditions produced different numerical estimates. A lower laboratory inhibition constant also cannot, by itself, rank the complete clinical effect of two drugs. Brain access, transporter substrate behavior, dose, exposure timing and other actions are separate parts of that comparison.
Even an animal comparison must retain its dosing design
One set of experiments summarized in the review measured extracellular norepinephrine in prefrontal cortex and dopamine in striatum of freely moving spontaneously hypertensive rats. The figure used intraperitoneal d-amphetamine doses of 0.3 and 1 mg/kg, and l-amphetamine doses of 1 and 3 mg/kg, with six to 11 animals contributing to the reported data points.
Those are different dose ranges, not an equal-dose human comparison. The measured changes were brain extracellular neurotransmitter signals relative to baseline. They were not blood amphetamine concentrations, human symptom scores or driving performance. Preserving the route, species and measured compartment prevents an attractive mechanistic figure from becoming an unsupported clinical conclusion.
What can mechanism establish about performance?
A mechanism can explain why a drug deserves investigation and why two agents should not be assumed interchangeable. It cannot establish that raising a neurotransmitter necessarily improves every cognitive function, causes impairment at every concentration, or explains an individual’s conduct. Those propositions require outcome-specific human evidence and case-specific facts.
The useful historical lesson is precision: distinguish a transported releasing agent from a simple blocker, distinguish the monoamines and distinguish the experimental measurement from a human functional claim. The review’s dated product availability and regulatory descriptions are not being adopted as current guidance.
Source
Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present—a pharmacological and clinical perspective. Journal of Psychopharmacology. 2013;27(6):479–496. doi:10.1177/0269881113482532. Historical narrative review spanning in-vitro, animal and human evidence.
Leave a Reply